Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report

Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report

Pulmonary pleomorphic carcinoma (PPC) is a non‐small‐cell lung cancer, resistant to chemotherapy and no standard therapy has as yet been established. We herein report the case of a 59‐year‐old man with PPC who showed a long‐term response with durvalumab after chemoradiotherapy. He was referred to ou...

Full description

Bibliographic Details
Main Authors:	Takafumi Yorozuya, Tetsuya Taya, Kento Yasuda, Yutaro Nagano, Makoto Shioya, Hirofumi Chiba, Hiroki Takahashi
Format:	Article
Language:	English
Published:	Wiley 2020-04-01
Series:	Thoracic Cancer
Subjects:	Chemoradiotherapy durvalumab immune checkpoint inhibitor pleomorphic carcinoma programmed death‐ligand 1
Online Access:	https://doi.org/10.1111/1759-7714.13331

Similar Items

Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post‐operative recurrent pulmonary pleomorphic carcinoma
by: So Shimamura, et al.
Published: (2021-06-01)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
by: Kageaki Taima, et al.
Published: (2020-07-01)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
by: Emma Sanderson, et al.
Published: (2020-04-01)

Retinal Vasculitis Secondary to Durvalumab
by: Antonio R. Andrade, et al.
Published: (2020-05-01)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
by: Yu Miura, et al.
Published: (2020-05-01)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
by: Takehiro Uemura, et al.
Published: (2021-09-01)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
by: Ryosuke Imai, et al.
Published: (2021-04-01)

Skin puckering and edema during durvalumab therapy
by: Brianna Olamiju, BA, et al.
Published: (2021-01-01)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
by: Galina B. Statsenko, et al.
Published: (2020-07-01)

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
by: J. Rotman, et al.
Published: (2018-09-01)

Phimosis: A rare complication of immunotherapy with durvalumab
by: Luis Gabriel Vázquez-Lavista, et al.
Published: (2020-11-01)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
by: Yoshiko Oshiro, et al.
Published: (2021-07-01)

Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
by: Shun Matsuura, et al.
Published: (2020-01-01)

Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
by: Kensuke Kanaoka, et al.
Published: (2020-06-01)

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
by: Rosalinda Arends, et al.
Published: (2021-01-01)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
by: Yang H, et al.
Published: (2018-07-01)

Durvalumab in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy in a real practice
by: Dina D Sakaeva, et al.
Published: (2019-09-01)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
by: Chia‐Hsun Chu, et al.
Published: (2020-06-01)

Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
by: Tadashi Sakaguchi, et al.
Published: (2021-07-01)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
by: Satoshi Saito, et al.
Published: (2020-07-01)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
by: Tanja Eichkorn, et al.
Published: (2020-12-01)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
by: Jean-David Fumet, et al.
Published: (2020-08-01)

Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer
by: Aokage, K., et al.
Published: (2022)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
by: Tomoya Fukui, et al.
Published: (2020-04-01)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
by: Kyoichi Kaira, et al.
Published: (2020-10-01)

The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report
by: Yoko Matsumoto, et al.
Published: (2017-08-01)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
by: Julian Taugner, et al.
Published: (2021-03-01)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
by: Narek Shaverdian, MD, et al.
Published: (2021-07-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
by: Albina S. Zhabina, et al.
Published: (2021-08-01)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
by: Eun Young Kim, et al.
Published: (2019-04-01)

IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report
by: Takeshi Terashima, et al.
Published: (2020-04-01)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
by: Fatima Karzai, et al.
Published: (2018-12-01)

Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report
by: Eriko Fujimoto, et al.
Published: (2018-05-01)

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
by: Gullapalli S, et al.
Published: (2020-07-01)

Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma
by: Yosuke Shionoya, et al.
Published: (2021-06-01)

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
by: Sehhoon Park, et al.
Published: (2019-05-01)

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
by: Houda Bahig, et al.
Published: (2019-01-01)

Immunohistochemical features of carcinoma ex pleomorphic adenoma and pleomorphic adenoma in the lacrimal gland
by: Ping Zhang, et al.
Published: (2019-08-01)